Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EpiDestiny

- PMLiVE

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Halts three studies because of safety concerns

- PMLiVE

Novo Nordisk awakens its ‘Sleeping Beauty’

Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott

- PMLiVE

New drugs drive Novo Nordisk despite insulin price pressures

Sales growth of new products up in Q4 but trouble forecasted this year

- PMLiVE

Novo Nordisk gets MACE prevention claim for Ozempic in US

Key product for the future growth of Novo's diabetes franchise

- PMLiVE

Lilly extends range of cut-price insulins in the US

Announces discounts in response to increasing pricing criticism

- PMLiVE

Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany

Will offer treatment via an outcomes-based payment model

- PMLiVE

Bluebird bio’s sickle cell gene therapy shows early-study benefit

Closely follows approval of beta thalassaemia therapy Zynteglo

- PMLiVE

FDA backs GBT’s sickle cell drug Oxbryta

Second new treatment for blood disorder to be approved this year

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

Novo bolstered by new diabetes, obesity products

Danish drug-maker has now raised its full-year sales forecast

- PMLiVE

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

- PMLiVE

Novo Nordisk taps Noom for digital help with its push into obesity

Could help to strengthen Saxenda franchise in treatment of obesity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links